# Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

> **NCT02034981** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 246 (actual)

## Conditions studied

- Hematologic Cancers
- Solid Tumors
- Metastatic Cancer

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT02034981
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2019-06
- **Final completion:** 2023-12-06
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034981, "Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02034981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*